2-甲基-1,4-氧杂氮杂环庚烷 | 1018614-41-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧氮杂卓类
• 中文名称: 2-甲基-1,4-氧杂氮杂环庚烷
• 英文名称: 2-Methyl-1,4-oxazepane
• CAS: 1018614-41-9
• 化学式: C₆H₁₃NO
• mdl: MFCD10035564
• 分子量: 115.17
• InChiKey: HQKJQSCCAMQSPY-UHFFFAOYSA-N

物化性质

• 沸点：
  163.5±23.0 °C(Predicted)
• 密度：
  0.877±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-[1,4] OXAZÉPANE-4-PYRIMIDONE
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2010114179A1

  公开（公告）日：2010-10-07

  A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C-F or the like; R1 represents a C1-C3 alkyl group; Y represents oxygen atom or N-R7; R2, R3, R4, R5, R6 and R7 each independently represents hydrogen atom, a C1-C6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I）或其药学上可接受的盐：其中Z代表氮原子，C-F或类似物；R1代表C1-C3烷基基团；Y代表氧原子或N-R7；R2、R3、R4、R5、R6和R7分别独立地代表氢原子，C1-C6烷基基团，或由化学式（II）表示的基团：该化合物用于预防和/或治疗由tau蛋白激酶1过度活化引起的疾病，如神经退行性疾病（例如阿尔茨海默病）。
• 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES
  申请人：Watanabe Kazutoshi

  公开号：US20120095216A1

  公开（公告）日：2012-04-19

  A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C—F or the like; R 1 represents a C 1 -C 3 alkyl group; Y represents oxygen atom or N—R 7 ; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 each independently represents hydrogen atom, a C 1 -C 6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

  化合物的化学式为（I）或其药学上可接受的盐，用于治疗由tau蛋白激酶1过度活化引起的疾病，例如神经退行性疾病（如阿尔茨海默病）。其中，Z代表氮原子、C—F或类似物；R1代表C1-C3烷基；Y代表氧原子或N—R7；R2、R3、R4、R5、R6和R7各自独立地代表氢原子、C1-C6烷基或由式（II）表示的基团。
• NOVEL TRIAZINE COMPOUNDS
  申请人：Dugar Sundeep

  公开号：US20130303516A1

  公开（公告）日：2013-11-14

  The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/or the mTOR pathway.

  本发明涉及公式（1）的新型三嗪类化合物，其制备方法、含有这些化合物的药物组合物以及使用这些化合物治疗增殖性疾病，如肿瘤和癌症，以及与PI3激酶、PI3激酶途径、mTOR和/或mTOR途径失调相关或相关的其他状况和疾病。
• HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1
  申请人：Diaz Frank

  公开号：US20090143357A1

  公开（公告）日：2009-06-04

  Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division, also are disclosed.

  本发明揭示了在治疗与DNA损伤或DNA复制中的损伤有关的疾病和状况中有用的替代脲化合物。本发明还揭示了制备这些化合物的方法，以及它们作为治疗剂的用途，例如，在治疗癌症和其他以DNA复制缺陷，染色体分离或细胞分裂为特征的疾病中。
• [EN] SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF<br/>[FR] INHIBITEUR À PETITES MOLÉCULES DE LA CATHEPSINE C ET SON UTILISATION MÉDICINALE<br/>[ZH] 组织蛋白酶C小分子抑制剂及其医药用途
  申请人：REISTONE BIOPHARMA COMPANY LTD

  公开号：WO2022117059A1

  公开（公告）日：2022-06-09

  本公开涉及组织蛋白酶C小分子抑制剂及其医药用途。具体而言，本公开提供了一种式VI所示的酰胺腈类化合物、含有该化合物的药物组合物以及其抑制组织蛋白酶C的用途。